{
    "root": "de5fd122-9f44-4685-87ec-77ecefa653c7",
    "code": "34391-3",
    "codeSystem": "2.16.840.1.113883.6.1",
    "displayName": "HUMAN PRESCRIPTION DRUG LABEL",
    "name": "AMVUTTRA",
    "value": "20250325",
    "ingredients": [
        {
            "name": "VUTRISIRAN SODIUM",
            "code": "28O0WP6Z1P"
        },
        {
            "name": "WATER",
            "code": "059QF0KO0R"
        },
        {
            "name": "Sodium hydroxide",
            "code": "55X04QC32I"
        },
        {
            "name": "Phosphoric acid",
            "code": "E4GA8884NN"
        },
        {
            "name": "SODIUM PHOSPHATE, MONOBASIC, DIHYDRATE",
            "code": "5QWK665956"
        },
        {
            "name": "SODIUM PHOSPHATE, DIBASIC, DIHYDRATE",
            "code": "94255I6E2T"
        },
        {
            "name": "Sodium chloride",
            "code": "451W47IQ8X"
        }
    ],
    "indications": "amvuttra transthyretin-directed small interfering rna indicated treatment : polyneuropathy hereditary transthyretin-mediated amyloidosis adults ( 1.1 ) cardiomyopathy wild-type hereditary transthyretin-mediated amyloidosis adults reduce cardiovascular mortality , cardiovascular hospitalizations urgent heart failure visits ( 1.2 )",
    "contraindications": "recommended amvuttra 25 mg administered subcutaneous injection every 3 months . ( 2.1 ) amvuttra subcutaneous administered healthcare professional . ( 2.2 )",
    "warningsAndPrecautions": null,
    "adverseReactions": "none .",
    "indications_original": "AMVUTTRA is a transthyretin-directed small interfering RNA indicated for the treatment of: the polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults ( 1.1 ) the cardiomyopathy of wild-type or hereditary transthyretin-mediated amyloidosis in adults to reduce cardiovascular mortality, cardiovascular hospitalizations and urgent heart failure visits ( 1.2 )",
    "contraindications_original": "The recommended dosage of AMVUTTRA is 25 mg administered by subcutaneous injection once every 3 months. ( 2.1 ) AMVUTTRA is for subcutaneous use only and should be administered by a healthcare professional. ( 2.2 )",
    "adverseReactions_original": "None."
}